This is a prospective study to evaluate effect of Exenatide extended release treatment for 1
year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to
Drug: Exenatide Extended Release for Inj Susp 2 MG
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT03029351
Ages eligible for Study
18 Years to 85 Years
Genders eligible for Study
Accepts Healthy Volunteers
Type 2 Diabetes for at least 1 year.
Microalbuminuria for at least 6 months (UACR: 30-300 mg/g)
Macroalbuminuria for at least 6 months (UACR: >300 mg/g)
HbA1c of ≤10%
Ages 18-65 years (inclusive of ages 18 and 65)
On ARBs/ACEi for at >3months
Use of GLP-1 Receptor agonists or SGLT-2 inhibitors therapy in the last 3 months
History or risk for pancreatitis (e.g., history of gallstones, alcohol abuse, and hypertriglyceridemia)
Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous 3 months
Hepatic disease: Severe hepatic insufficiency and/or significant abnormal liver function defined as:
Aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN
Total bilirubin >2.0 mg/dL (34.2 µmol/L)
Positive serologic evidence of current infectious liver disease including Hepatitis B viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody
Liver function tests more than 3 times the upper limit of normal
Renal impairment (serum eGFR <30 ml/min)
Inability to give informed consent
History of gastroparesis
History of medullary thyroid carcinoma or MEN 2 syndrome
Hypertriglyceridemia (>500 mg/dl).
Any other life-threatening, non-cardiac disease
Uncontrolled hypertension (BP > 160/100 mm of Hg)
Congestive Heart Failure class III or IV
Use of an investigational agent or therapeutic regimen within 30 days of study
Participation in any other concurrent clinical trial
Pregnant or breastfeeding patients or females of childbearing age not on 2 forms of acceptable contraceptives.
All locations for NCT03029351
View full eligibility
Tris trial is registered with FDA with number: NCT03029351. The sponsor of the trial is University at Buffalo and it is looking for 90 volunteers for the current phase.
Official trial title: GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.